49
Emerging and Rare Viral Infections in Transplantation
Staci A. Fischer

Viral infections are common following solid organ and hematopoietic stem cell transplantation, as detailed in other chapters. While cytomegalovirus (CMV) remains the most prominent virus in transplantation, and the clinical manifestations and complications of infection with other herpesviruses (e.g., herpes simplex virus, Epstein-Barr virus, and human herpesviruses 6 and 8) are well described, improvements in diagnostic techniques have led to the recognition of a number of additional viruses with potential pathogenicity in the immunocompromised host. Outbreaks of emerging viruses, the resurgence of vaccine-preventable viral infections, and the identification of viruses which cause self-limited infection in immunocompetent children but significant disease in transplant recipients have highlighted the breadth of pathogens in this patient population. Some of these emerging and unusual viral pathogens are discussed in alphabetical order below.

49.1 Astrovirus
Astrovirus is a common cause of viral gastroenteritis throughout the world and has been a cause of outbreaks of diarrheal disease in schools, hospitals, nursing homes, and military bases [1–3]. Several recent reports have highlighted the impact of this RNA virus on immunocompromised hosts. In addition to its role in gastroenteritis in these patients, one astrovirus subgroup (VA1/HMO-C) has been reported to cause encephalitis in allogeneic hematopoietic stem cell transplant (HSCT) recipients and children with X-linked agammaglobulinemia [4, 5]. Molecular techniques including reverse-transcription polymerase chain reaction (RT-PCR), RNA sequencing, and next-generation sequencing have demonstrated the presence of this subgroup in the cerebrospinal fluid (CSF) and brain tissue of infected patients. Immunohistochemical staining on biopsy tissue has confirmed the presence of invasive infection. There are no known antiviral treatments available, and central nervous system (CNS) infection has been fatal in the cases reported to date. Additional study is needed to determine the prevalence of astrovirus infection in transplanted patients.

49.2 Bocavirus
Bocavirus is a human parvovirus that causes upper and lower respiratory tract infection, gastroenteritis, and encephalitis in children [6, 7]. Infection is most common in the late fall and winter, and most commonly presents with rhinorrhea, fever, cough, wheezing, or diarrhea. Thirty percent of children develop hypoxia, and a variety of radiographic findings have been reported, including peribronchial cuffing, lobar infiltrates, and pleural effusions. Nosocomial infection has occurred [8]. Bocavirus infection has been reported in the first few weeks following hematopoietic stem cell transplantation, presenting with fever, rhinorrhea, cough, diarrhea, and hypoxia [9]. Virus has been detected in high quantities in plasma, nasopharyngeal aspirates, and stool. Fecal shedding occurs for several weeks to months after clinical resolution of infection [10]. Severe and prolonged diarrhea has been described in liver transplant and hematopoietic stem cell recipients [11]. It has been suggested that bocavirus, like respiratory syncytial virus (RSV) and parainfluenza, may play a role in the development of bronchiolitis obliterans, a manifestation of chronic rejection in lung transplantation [12–14]. To date, there are no data on antiviral efficacy against bocavirus.

49.3 Chikungunya Virus
Chikungunya virus, a mosquito-borne alphavirus transmitted by *Aedes aegypti* and *Aedes albopictus*, is a tropical infection which has caused epidemic disease in India, Thailand, Malaysia, Madagascar, and Reunion Island [15, 16]. It is endemic in eastern, central, and southern Africa. In 2013, chikungunya was reported in St. Martin, with epidemic
spread throughout the Caribbean, Central America, South America, and Florida, where infection spread locally via *A. aegypti* [17].

After an incubation period of 2–4 days, infection presents with high fever, headache, myalgias, and arthralgias, and can resemble dengue. Arthralgias are typically symmetric and involve large joints, particularly in the legs and arms. Frank arthritis may also occur in the interphalangeal joints, wrists, and ankles. Half of patients also develop a rash, which can be maculopapular, petechial, or bullous and is most commonly located on the trunk, with occasional involvement of the face, extremities, palms, and soles. Ocular pain has also been reported. Rarely, meningoencephalitis, myocarditis, or hepatitis can occur. Symptoms resolve in 7–10 days, although arthralgias and joint stiffness may persist for weeks to months after fever resolves. Severe manifestations of infection with fatal outcomes have been reported in patients with underlying diabetes, lung disease, or chronic neurologic conditions.

Laboratory findings include lymphopenia, thrombocytopenia, elevated transaminases, and hypocalcemia. Diagnosis may be made serologically or by RT-PCR. IgM antibodies develop as fever resolves, typically 1 week after symptom onset. There is currently no known effective antiviral therapy for chikungunya.

During a widespread outbreak of infection on Reunion Island in the Indian Ocean, organ and tissue donors were screened for the presence of chikungunya infection [18]. Corneal donors were found to have serologic and PCR evidence of infection in serum and corneal tissue. Transmission of infection with corneal transplantation is presumed to occur. There have been no reports of transmission of chikungunya in solid organ or stem cell transplantation to date although with reports of infection in Asia, Europe, and North America in travelers from endemic areas, the risk of transmission and the clinical course of infection in these patients require further study.

### 49.4 Coronavirus

In February 2003 a worldwide outbreak of severe respiratory infection occurred, infecting more than 8000 patients over several months in 29 countries, most severely affecting southern China, Hong Kong, and Canada, with well-described healthcare-associated outbreaks [19–26]. Eighty percent of those affected were previously healthy, with no comorbid conditions. The outbreak began in Guangdong Province, China, in November 2002 and with global travel spread rapidly to multiple continents. The infection of numerous health care workers and the rapidly fatal course of infection, even in healthy hosts, were remarkable. Named Severe Acute Respiratory Syndrome (SARS), this infection was quickly determined to be due to a new strain of coronavirus, a group of viruses known to cause human disease since the 1960s [27].

Patients initially noted high fever, myalgias, headache, and cough, and subsequently became dyspneic [19, 20, 25, 28]. A productive cough was seen in nearly one third of patients, while rash and lymphadenopathy were absent. Lymphopenia, thrombocytopenia, mild elevation of transaminases, prolonged prothrombin time with elevated D-dimers, elevated lactate dehydrogenase (LDH) and creatine kinase (CK), and hyponatremia were common lab findings [25]. Chest radiographs revealed focal airspace consolidation or ground glass opacities, initially without the interstitial infiltrates most characteristic of viral pneumonitis, with lower lung field predominance [22, 25]. Pleural effusions and mediastinal lymphadenopathy were generally absent. Histopathologic findings in lung biopsies and at autopsy included diffuse alveolar damage consistent with adult respiratory distress syndrome (ARDS), with significant alveolar edema, minimal inflammation, and no viral inclusions.

Treatment included corticosteroids and intravenous or oral ribavirin. Although published data are not yet available in humans, animal models suggest that monoclonal antibody to SARS coronavirus (SARS-CoV) is effective in decreasing viral replication and improving outcomes [26]. The overall case fatality rate during the SARS epidemic was nearly 10% [19]. A novel coronavirus was rapidly isolated and identified as the cause of SARS and sequenced, allowing for RT-PCR and serologic testing to be developed [29, 30].

During the SARS outbreak in Toronto, a liver transplant recipient was fatally infected while visiting a medical center for an outpatient clinic visit nearly 10 years posttransplant [31]. Disseminated infection was described in a lung transplant recipient in whom virus was detected in lungs, bowel, lymph nodes, liver, kidney, skeletal muscle, and brain at autopsy [32, 33]. Tissue viral loads were significantly higher in transplant recipients than in their immunocompetent counterparts [34]. The last of the nearly 8000 reported cases of SARS-CoV was reported in May 2004, after which no additional cases have been reported, for unclear reasons.

In September 2012, initial reports of infection with another novel human coronavirus began in Saudi Arabia, with rapid spread to neighboring Egypt, Iran, Jordan, Kuwait, Lebanon, Qatar, Oman, Yemen, and the United Arab Emirates, then to other continents with airline travel [35]. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) has been reported to cause severe respiratory tract infection in adult patients, with a mortality rate as high as 60%, most commonly in those with diabetes mellitus and end stage renal disease [36]. After a median incubation period of 5 days (range, 2–14 days), patients often present with fever, cough, dyspnea, and diarrhea after close contact with an infected case and/or travel from an area where infection is active. Coryza, headache, nausea, vomiting, and abdominal pain have also been reported [37]. Laboratory findings include thrombocytopenia, leukopenia, lymphopenia, and elevated...
transaminases and LDH. Coinfection with other respiratory viruses has been reported [38]. As with SARS-CoV, health care workers are at risk for infection [39, 40]. Dromedary camels have been reported to harbor infection in the Arabian Peninsula, although the mode of transmission of infection has not yet been elucidated [41].

Several cases of MERS CoV infection have been reported in hematopoietic stem cell and solid organ transplant recipients, who have developed bilateral pulmonary infiltrates with respiratory failure, acute renal failure, leukopenia, thrombocytopenia, and elevated transaminases, at times without fever [36, 42].

While difficult to grow in cell culture, MERS CoV may be diagnosed by RT-PCR on respiratory secretions. Virus has been detected with these techniques in urine and stool as well. To increase the yield of testing, it is recommended that multiple specimens from different sites (e.g., nasopharyngeal swab, sputum, BAL fluid, serum, and stool) be tested using RT-PCR, which is available from the CDC and local health departments in the USA [37]. Due to the risk of transmission of infection to health care workers, contact and airborne precautions are recommended in caring for the suspected MERS-CoV infected patient [39, 40].

While there have been no randomized, controlled clinical trials of antivirals against MERS-CoV, ribavirin and mycophenolate mofetil (an immunosuppressive agent used commonly in transplantation) have in vitro activity against the virus [43]. Ribavirin (in combination with interferon α-2b) has demonstrated promise in decreasing lung injury and viral replication in rhesus macaques infected with MERS-CoV [44]. A retrospective cohort study describing the use of ribavirin and interferon α-2a in twenty patients with severe infection demonstrated an early survival benefit [45].

Whereas coronaviruses made world headlines with the SARS epidemic in 2002–2004 and the MERS-CoV emergence in 2012, coronaviruses OC43 (group 1) and 229E (group 2) have been known for decades to cause upper respiratory tract infections during the fall and winter months. Coronavirus NL63 (group 1) has been reported to cause upper and lower respiratory tract infections in immunocompetent hosts in the Netherlands, and coronavirus HKU1 (group 2) has been reported to cause pneumonia in Hong Kong and France [21]. Non-SARS coronaviruses have recently been associated with severe lower respiratory tract infections in hospitalized patients, including lung and liver transplant recipients [46]. Coronavirus 229E has been isolated from hematopoietic stem cell transplantation recipients with fever and cough associated with interstitial and alveolar pulmonary infiltrates [46]. Pancytopenia may be present. Radiographic infiltrates are most commonly interstitial, although 28% are alveolar. Pleural effusions may be present, and pneumothorax has been noted in a minority of patients. Diagnosis may be made by culture in human hepatoma HUH7 cell line, or by RT-PCR [46, 47].

49.5 Hepatitis E

Hepatitis E is endemic in developing countries and has been reported to cause epidemic disease in Asia, Africa, and Latin America via fecal–oral transmission [48]. Travel-related infection has been reported in those returning from endemic areas with poor sanitation. Recent reports have highlighted the important role of this infection in transplant recipients.

Hepatitis E virus (HEV) is an RNA virus with four major genotypes with presumed reservoirs in pigs, wild boars, deer, and mollusks [49, 50]. Seroprevalence surveys indicate that infection in blood donors, even in France and the USA, is significant; in some areas, hepatitis E is more prevalent than hepatitis A [51, 52]. Epidemics of infection have been described from ingestion of contaminated water, mollusks, and undercooked deer, boar, or pig meat [53–55]. Blood transfusion-transmitted infection has also been described [56–59]. After an incubation period of two to nine weeks, patients develop jaundice, abdominal pain, anorexia, and nausea. Fever and chills may occur as well, although rash is unusual. Diagnosis can be made by RT-PCR detection of HEV RNA, which is present between 2 and 6 weeks after infection, as symptoms occur [60]. IgM antibodies develop as symptoms resolve, approximately 4 weeks after infection. Elevated transaminases occur, peaking approximately 6 weeks after infection. While viremia resolves within 6 weeks of infection, virus remains detectable in stool for several weeks after viremia resolves and IgG appears. Serum IgG antibodies persist for years after acute infection.

Approximately 10% of patients with acute HEV infection develop fulminant hepatitis with acute hepatic failure; the presence of pregnancy or underlying chronic liver disease (e.g., chronic hepatitis C infection or cirrhosis) increases the risk for severe infection [61, 62]. Histopathologic findings on liver biopsy include lymphocytic infiltration of portal triads. Chronic hepatitis appears to be rare in immunocompetent hosts.

Disease in organ transplant recipients has been characterized by a high incidence of chronic infection (in up to 60% of acutely infected patients) with progressive fibrosis and eventual cirrhosis [63–66]. Reactivation of infection has been described in liver and allogeneic HSCT recipients, in whom nearly half of infections became chronic [67–69]. Liver transplant recipients appear to be at increased risk for chronic infection resulting from reactivation of HEV after transplantation, as well as acute graft hepatitis from reactivation or primary infection [70]. Extrahepatic manifestations of infection in transplant recipients have included glomerulonephritis and neurologic involvement [69, 71].

There are no FDA-approved therapies for HEV infection, although decreasing immunosuppression appears to have helped control viremia in some chronically infected transplant recipients. In small studies, interferon alpha and ribavirin have been reported to decrease viremia in these patient populations [72, 73].
49.6 Lymphocytic Choriomeningitis Virus

Lymphocytic choriomeningitis virus (LCMV) gained notoriety as a pathogen in solid organ transplantation in 2005, when the first two outbreaks of donor-transmitted infection were described [74–76]. Additional donor-transmitted outbreaks have recently occurred in the USA and Australia [77–80]. Four clusters of donor-derived infection have occurred in the USA to date.

LCMV is a rodent-borne Old World arenavirus that causes asymptomatic or mild, self-limited illness in the immunocompetent host. Rodents, especially common house mice, laboratory mice, and hamsters, often acquire infection congenitally, resulting in lifelong, asymptomatic excretion of virus in urine, saliva, and feces [81–84]. Human infection occurs via direct contact with infected rodents or aerosolized infected excreta (e.g., with cleaning soiled cage bedding). Symptoms described in immunocompetent humans include fever, headache, and myalgias, with CSF findings consistent with aseptic meningitis (e.g., lymphocytic pleocytosis). In the normal host, infection is self-limited and carries a mortality rate of less than 1% [85].

In the transplant clusters, infection with LCMV has been fatal in more than 80% of cases [74, 78, 80]. Patients have presented within the first month posttransplant with fever, diarrhea, abdominal pain, and dyspnea. Rash, headache, lethargy, hypotension, and the presence of pulmonary infiltrates are variable. Thrombocytopenia and anemia have been present, with variable peripheral leukocyte and lymphocyte counts. Acute hepatitis with elevated transaminases has been noted, as well as coagulopathy with prolonged prothrombin times. Patients have developed rapidly progressive multisystem failure with encephalopathy prior to death. In one cluster, while the donor had no evidence of infection in multiple tissues tested, a pet hamster present in the donor’s home for several weeks prior to donation was found to have LCMV in multiple tissues [74]. Virus isolated from the hamster was identical to that isolated from the infected transplant recipients. The survivor in that cluster, a kidney recipient, was treated with discontinuation of all immune suppression except corticosteroids and with intravenous ribavirin. Similar approaches have been used in more recent cases [80].

With four donor-derived infection outbreaks in the USA alone, LCMV infection is likely more common than previously recognized in transplant recipients. Detailed workup of potential organ donors with aseptic meningitis or meningocencephalitis may prevent transmission in some cases. Whether LCMV infection occurs posttransplant in recipients with exposure to pet hamsters or house mice is unknown.

49.7 Metapneumovirus

Human metapneumovirus is a single-stranded RNA paramyxovirus of worldwide endemicity that causes respiratory tract infection in children, the elderly, and immunocompromised adults, with outbreaks reported in long-term care facilities [86–90]. Infection occurs in the late winter and early spring (January through April), similar to the seasonality of respiratory syncytial virus (RSV). Upper and lower respiratory tract symptoms, including rhinorrhea, sore throat, cough, dyspnea, and fever, have been described.

Infection has been described following lung and heart–lung transplantation, resulting in acute pneumonia with diffuse alveolar damage and hyaline membrane formation [91, 92]. Lung transplant recipients with metapneumovirus pneumonia have a 14% mortality rate and are at higher risk for acute and chronic rejection [92, 93]. In renal transplant recipients, pneumonitis due to metapneumovirus has been reported 3 years posttransplant [94]. In one study of HSCT recipients, human metapneumovirus was isolated via RT-PCR in 26% of symptomatic patients undergoing bronchoscopy and carried a mortality rate of 80% [95]. Infection occurred within the first few weeks following transplant, and was characterized by fever, nasal congestion, and cough, with rapid development of hypoxia, hypotension, and progressive pneumonia, with diffuse alveolar hemorrhage in three of five patients [94–96]. Pleural effusions and nodular infiltrates may be seen, which may help differentiate infection from RSV. Coinfection with RSV, rhinovirus, and CMV has been described following lung transplantation [97].

Ribavirin has been demonstrated to decrease human metapneumovirus replication in the lungs in a mouse model [98], and intravenous ribavirin has been effective in the treatment of several lung transplant recipients with metapneumovirus infection [99].

49.8 Measles

Measles outbreaks have occurred in multiple states in recent years, with an attack rate of greater than 90% among susceptible patients, including unvaccinated children and adults [100–108]. Affected patients develop fever, cough, and coryza, associated with a characteristic rash. Infection may be complicated by pneumonia, encephalitis, or dissemination, with significant mortality noted in solid organ and HSCT recipients [109]. Infection has been associated with waning immunity and is diagnosed serologically. There are no data on antivirals for treatment of measles.
49.9 Mumps

Mumps has been increasingly reported in the USA, with more than 10,000 cases reported in a large multistate outbreak in 2005–2006 [110–116]. Patients present with acute onset of unilateral or bilateral parotitis; infection may be complicated by orchitis, oophoritis, pancreatitis, mastitis, meningitis, and encephalitis [117]. Infection may be diagnosed serologically or via PCR [118, 119]. No antivirals have been investigated in the treatment of mumps. Enhanced efforts at immunization against measles and mumps pretransplant as well as active surveillance posttransplant are warranted.

As a result of the re-emergence of these vaccine-preventable viruses, recent guidelines suggest vaccination with the measles, mumps, and rubella (MMR) vaccine 2 years following hematopoietic stem cell transplantation in patients without evidence of graft-versus-host disease [120, 121]. If at all possible, patients undergoing solid organ transplantation who do not have evidence of protection against measles and mumps (e.g., positive IgG antibody to each) should be vaccinated prior to the initiation of immunosuppressive therapy.

49.10 Norovirus

Noroviruses are caliciviruses that cause over 20 million cases of gastroenteritis annually in the USA and over half of all epidemics of gastroenteritis worldwide [122–129]. Infection is acquired via consumption of contaminated foods (including raw oysters, fruit, and vegetables) or via ingestion of or swimming in contaminated water, with spread via fomites and from person to person [130–145]. Infection is extremely contagious and often spreads rapidly as a result of prolonged fecal shedding in affected patients after resolution of symptoms. Outbreaks of infection have been described in multiple settings including military barracks, restaurants, hospitals, long-term care facilities, schools, and cruise ships [122].

Infection may be asymptomatic or present with the sudden onset of nausea, vomiting, and diarrhea after an incubation period of less than 48 h. Some studies have suggested that vomiting is more common in children, with diarrheal symptoms predominating in infants and adults [138, 148]. Infection is most common in the winter months, with symptoms lasting 1–7 days [122, 142, 148]. Attack rates in some outbreaks have been 50–90%, with health care workers at substantial risk for infection [127, 130, 137–139, 144–147]. Noroviruses cannot be cultured in vitro, but RT-PCR and enzyme immunoassay (EIA) assays are available for diagnosis in stool specimens [148–150].

Norovirus infection in solid organ transplant recipients is common, and marked by risk for chronic and relapsing infection [150]. Infection presents with watery diarrhea, which can cause volume depletion and acute renal failure in renal transplant recipients [126, 142, 149, 151]. Patients may be symptomatic for months and may shed virus in stool for years. Hematopoietic stem cell transplant recipients have been reported to develop acute and chronic diarrheal disease from norovirus infection, which has been associated with the subsequent development of chronic GVHD [151, 152]. Receipt of cord blood, induction with fludarabine, and receipt of alemtuzumab have been reported to be risk factors for norovirus infection in this setting. Nosocomial outbreaks of infection in HSCT units have resulted in infection of staff and patients, with sepsis from bacterial translocation complicating several cases [152, 153].

Treatment of norovirus infection in transplant recipients has not been investigated in randomized, controlled trials to date. Reduction of immunosuppression resulted in clearance of infection in one intestinal transplant recipient with norovirus infection [154]. There are no available antiviral therapies to date. Noroviruses are highly resistant to disinfectants, propagating prolonged transmission in many environments.

49.11 Parvovirus B19

Parvovirus B19 infection is common, with 60–90% of adults having serologic evidence of prior infection [155]. In children, parvovirus infection causes erythema infectiosum, a febrile illness with a characteristic “slapped cheek” rash. Adults with acute parvovirus infection develop a flu-like illness, sometimes with resultant arthropathy. A pathogen of erythroid progenitor cells, parvovirus B19 causes severe anemia in patients with underlying hemolytic disorders and hydrops fetalis in pregnancy. In recent years, neurologic involvement including meningoencephalitis has been described, which may be more common in immunocompromised hosts [156, 157].

In transplant recipients, anemia is the most common presentation of infection. Fever occurs in 25% of patients and arthralgia or rash occurs in less than 10% of those affected [158]. Pancytopenia may be present. Other manifestations described in the transplant population include hepatitis, myocarditis, pneumonitis, encephalitis, meningitis, peripheral neuritis, and collapsing glomerulopathy [155, 157–160]. Those with CNS infection may develop sequela including seizures, cognitive deficits, stroke, and muscle wasting [157]. Donor-transmitted infection has been described, presenting with allograft dysfunction, fever, arthralgia, and pancytopenia, often without a rash [161–164]. Chronic or recurrent anemia may be seen posttransplant, as well as pure red cell aplasia [165, 166]. Parvovirus B19 infection has also been associated with the subsequent development of thrombotic microangiopathy in kidney transplant recipients, including a cluster of cases in Iran; hemophagocytic lymphohistiocytosis has also been described in this population [167, 168]. The significance of the frequent finding of parvovirus DNA in renal allografts pre- and posttransplant is under investigation [169]. In other transplant populations, parvovirus may be associated with chronic cellular allograft rejection [170].
Diagnosis of parvovirus B19 infection may be made by serology, PCR, or bone marrow examination in immunocompetent hosts. The yield of serologic testing (especially IgM) is limited in transplant recipients who may not mount an adequate antibody response to infection, so that RT-PCR on blood, bone marrow, or other involved tissues is necessary to detect infection in many cases [155]. Infection may respond to intravenous immunoglobulin (IVIg), with relapses occurring in up to 25% of immunosuppressed hosts [155]. There are no published data on the use of antivirals in parvovirus infection.

### 49.12 Polyoma Viruses (KI, WU, and Merkel Cell Carcinoma Polyomaviruses)

Human polyoma viruses such as BK virus and JC virus are well known pathogens in transplantation and are discussed elsewhere. In recent years three additional polyoma viruses have been described as potential pathogens in immunocompromised hosts. Like BK and JC, these viruses frequently cause asymptomatic primary infection in healthy patients and are capable of establishing latent infection which can be reactivated in the setting of immune suppression. KI and WU viruses (named for the institutions in which they were discovered, Karolinska Institutet and Washington University) have been isolated in children with acute respiratory symptoms including wheezing as well as in the setting of pneumonia [171, 172]. Respiratory infection has also been described in HIV-infected patients, in whom higher viral loads have been demonstrated in those with lower CD4 counts [173].

KI and WU polyomaviruses have been isolated in nasopharyngeal, sputum, and bronchoalveolar lavage specimens in hematopoietic stem cell and solid organ transplant recipients [174, 175]. These viruses have also been detected in transbronchial biopsy specimens in lung transplant recipients, who in many cases were asymptomatic. Coinfection with other viral and bacterial pathogens has been reported. RT-PCR results should be interpreted with caution in transplant recipients, in whom severe infection has not been described to date. There are no available data on the role of decreasing immunosuppressive therapy or the use of antiviral agents in the development or treatment of infection with KI and WU polyomaviruses.

Merkel cell carcinoma is a neuroendocrine malignancy of the skin which is most common in immunocompromised hosts including transplant recipients [173, 176]. Over 80% of these tumors contain a polyoma virus named Merkel Cell polyomavirus (MCPyV); virus has also been found in respiratory secretions in asymptomatic transplant recipients. Further study of each of these polyomaviruses is ongoing in the transplant population.

### 49.13 Rotavirus

Rotavirus, the most common cause of enteritis worldwide and a common pathogen in healthy children under the age of 3, has become increasingly recognized as a pathogen in pediatric and adult recipients of solid organ transplants [177]. Epidemics have occurred through fecal–oral transmission, primarily in the winter and spring. Affected patients present with watery diarrhea, nausea, vomiting, abdominal pain, and, in some cases, gastrointestinal bleeding from colonic ulcers. Infection may be diagnosed by antigen detection in stool specimens using ELISA, latex agglutination, or quantitative PCR. Infection is generally self-limited with weaning immunosuppression during the acute phase of illness. There are no published data on antiviral activity against rotavirus; treatment remains symptomatic.

Rotavirus has been associated with a high risk of acute cell-mediated rejection in intestinal transplant recipients, which has been proposed to be related to poor absorption of immunosuppressive agents in the setting of vomiting and diarrhea, as well as immune reactivation of gastrointestinal tract-associated lymphocytes in the setting of infection [178]. In HSCT recipients, rotavirus infection may be difficult to differentiate clinically and histopathologically from GVHD.

In 1998, a live, oral, tetravalent rhesus–human reassortment rotavirus vaccine (RotaShield, Wyeth-Ayerst Laboratories, St. David, PA) was licensed and recommended for routine immunization of infants in the USA; it was voluntarily withdrawn from the market in 1999 due to its association with intestinal intussusception noted in postmarketing surveillance [179–181]. Two additional Rotavirus vaccines have been studied (RotaTeq, Merck & Company, Whitehouse Station, NJ; Rotarix, GlaxoSmithKline Biologicals, Rixensart, Belgium). Both vaccines are oral and contain live virus, and are thus contraindicated in highly immunocompromised patients. Fecal virus shedding has been noted with both vaccines, with transmission of vaccine-associated virus to household members noted with Rotarix [181].

Current vaccination guidelines in immunocompromised hosts recommend that HSCT and solid organ transplant recipients not receive this live virus vaccine. Household contacts of patients with immune deficiency may be vaccinated, but the transplant recipient should not change diapers for 4 weeks after vaccination, the usual duration of viral shedding in stool [182].

### 49.14 West Nile Virus

West Nile virus (WNV) was initially isolated from a febrile patient in the West Nile Province in Uganda in the 1930s and has been enzootic in Africa, Asia, the Middle East, and parts of the Mediterranean and Europe, causing asymptomatic disease
or a self-limited febrile flu-like illness [183]. This flavivirus was first detected in the northeastern USA in 1999 and has caused outbreaks of infection in the late summer and early fall throughout the USA since then [184, 185]. Birds are the primary reservoir of infection. Mosquitoes acquire lifelong infection after biting viremic birds, spreading infection from their salivary glands to other species, including humans, with a subsequent bite. In human infection, the incubation period is 2–14 days [186]. While approximately 80% of infections are asymptomatic, 20% of patients develop West Nile fever, characterized by fever, malaise, anorexia, nausea, myalgias, headache, and occasionally lymphadenopathy [187]. One in 150 symptomatic patients develops meningitis and/or encephalitis [188]. Meningitis presents with photophobia, phonophobia, meningismus, and hyporeflexia; CSF analysis reveals a lymphocytic pleocytosis (<500 leukocytes/mm³, glucose usually normal). Patients with encephalitis develop altered mental status, cranial nerve palsies, seizures, and movement disorders. A minority of patients develop rapid asymmetric weakness that may progress to flaccid paralysis mimicking poliomyelitis, associated with hyporeflexia or areflexia [184, 189, 190]. Acute neuromuscular respiratory failure may develop, which carries a mortality rate of more than 50% [188]. Hemorrhagic fever characteristic of other flaviviruses has also been described [191]. The presence of severe weakness and hyporeflexia in a patient with meningoencephalitis should raise the suspicion of WNV infection. MRI may demonstrate meningeal or periventricular enhancement, sometimes mimicking ischemic changes [186].

Transmission of WNV via dialysis has been suggested [192], and transmission via blood transfusion and organ transplantation has been well documented [193–197]. In immunocompromised hosts, central nervous system involvement is common, although CSF pleocytosis may be minimal [198–200]. Community-acquired infection has been reported following solid organ transplantation, occurring 2 months to 10 years posttransplant [185, 199–202]. A study of WNV infection during an outbreak in Toronto noted that liver, kidney, and heart transplant recipients had 40 times the risk of symptomatic infection as normal hosts [203]. In all cases, the recipients had participated in outdoor activities without the use of insect repellent or other personal protective measures. Fever often preceded neurologic symptoms. A delayed serologic response was noted in the transplanted cohort in which infection carried a mortality rate of 25%, versus 9% in the general population. In a Colorado outbreak in 2003, 11 transplant recipients (4 kidney, 2 liver, 2 kidney/pancreas, 1 lung, and 2 HSCT) developed infection requiring hospitalization [204]. Ten (91%) developed meningoencephalitis, one developed acute flaccid paralysis without encephalitis, and three patients had meningoencephalitis and paralysis. Two patients died (18% mortality), and three suffered significant neurologic sequelae. It appears that transplant recipients are more likely to develop meningoencephalitis in the setting of acute West Nile virus infection than immunocompetent hosts, perhaps with a higher mortality rate. Prolonged infection can also occur [205].

Several cases of WNV infection have been reported in HSCT recipients [206, 207]. Infection occurred 3–5 months posttransplant in the most well-described cases, after engraftment but while on calcineurin inhibitor-based prophylaxis or treatment of chronic graft-versus-host disease. Fever, lethargy, progressive bilateral extremity weakness, and hyporeflexia or areflexia were present. CSF contained 0–6 white blood cells/μL; IgG and IgM were negative in CSF and{\text{blood}}{\text{in most}}{\text{cases. Diagnosis of WNV infection was made by PCR performed on serum and CSF. All of the described patients died.}}

Diagnosis of WNV infection in immunocompetent hosts may be made serologically or via RT-PCR. An IgM antibody capture assay is available and becomes positive in CSF 3–5 days after onset of symptoms in nonimmunosuppressed hosts [202, 207], before serum antibody develops; CSF IgG appears approximately 5 days later. Antibody presence may be confirmed with viral neutralization studies. IgM antibodies may persist in serum for up to 12 months after infection resolution, and IgG may persist for years. As in the hematopoietic stem cell recipients noted above, immunocompromised patients demonstrate delayed seroconversion, making diagnosis of acute infection difficult at times. Nucleic acid testing in plasma and/or CSF is the most useful diagnostic test in this setting [208].

There are no antiviral agents that have proven efficacy in the treatment of WNV infection. Ribavirin possesses in vitro activity but demonstrates poor clinical efficacy [186, 209]. IVIg with high titters of anti-WNV antibodies (e.g., from Israel, where infection is endemic) has demonstrated significant clinical benefits in animal models, although antibody titters are low in immune globulin derived from the US donors, which have proven ineffective in treating acute infection [184, 210, 211]. A report of successful treatment of donor-transmitted WNV infection in a liver transplant recipient by reducing immunosuppression and administering plasma from seropositive blood donors has been published [212]. Overall case fatality rates of infection with WNV are 4–20% [189, 192], with significantly higher rates in transplant recipients.

Unlike the case in other neuroinvasive viral infections, the severity of initial clinical presentation does not predict the prognosis of WNV infection [187, 190, 213]. Survivors frequently suffer from prolonged fatigue, myalgias, cognitive deficits, memory loss, and tremors. Parkinsonism, excessive somnolence, and postural instability are reported. Phase I trials of a vaccine have been promising [214]. Transplant recipients should be educated about the transmission of West Nile virus and urged to remove any stagnant water collections and to use insect repellent when outdoors at dusk during the later summer and fall in order to prevent infection.
49.15 Conclusion

Viruses remain the most significant and elusive pathogens infecting patients following solid organ and hematopoietic stem cell transplantation. The days of “it’s just a virus” are clearly behind us, as immunosuppression has changed, post-transplant longevity is increasing, and molecular diagnostic methods have dramatically improved [215]. Serology may be of limited value in immunocompromised hosts in the diagnosis of acute infection as well as in detecting reactivation of latent infections. Multiplex, quantitative real-time PCR assays are now available to detect multiple viruses, including panels of PCRs for detection of respiratory viruses and CNS pathogens [216, 217]. These sensitive techniques are being evaluated carefully in transplant populations for their specificity and for their potential utility as markers of early infection with surveillance monitoring. The impact of community-acquired respiratory viral infections on the development of acute rejection and bronchiolitis obliterans in lung transplantation appears to be significant and warrants further study [218, 219]. Continued vigilance in detecting emerging viral infections and continued study of potential antiviral therapies in the transplant population will likely improve patient survival.

References

1. Palombo EA, Bishop RF. Annual incidence, serotype distribution, and genetic diversity of human astrovirus isolates from hospitalized children in Melbourne, Australia. J Clin Microbiol. 1996;34:1750–3.
2. Lewis DC, Lightfoot NF, Cubitt WD, Wilson SA. Outbreaks of astrovirus type 1 and rotavirus gastroenteritis in a geriatric in-patient population. J Hosp Infect. 1989;14:9–14.
3. Lopes-Joao A, Costa I, Mesquita JR, et al. Multiple enteropathogenic viruses in a gastroenteritis outbreak in a military exercise of the Portuguese army. J Clin Virol. 2015;68:73–5.
4. Naccache SN, Peggs KS, Mattes FM, et al. Diagnosis of neuroinvasive astrovirus infection in an immunocompromised adult with encephalitis by unbiased next-generation sequencing. Clin Infect Dis. 2015;60:919–23.
5. Brown JR, Morfooupolou S, Hubb J, et al. Astrovirus VA1/ HMO-C: an increasingly recognized neurotropic pathogen in immunocompromised patients. Clin Infect Dis. 2015;60:881–8.
6. Kesebir D, Vazquez M, Weibel C, et al. Human bocavirus infection in young children in the United States: molecular epidemiological profile and clinical characteristics of a newly emerging respiratory virus. J Infect Dis. 2006;194:1276–82.
7. Cheung W-X, Jin Y, Duan Z-J, et al. Human bocavirus in children hospitalized for acute gastroenteritis: a case–control study. Clin Infect Dis. 2008;47:161–7.
8. Campe H, Hartberger C, Sing A. Role of human bocavirus infections in outbreaks. J Clin Virol. 2008;43:340–2.
9. Mitui MT, Bin Tabib SMS, Matsumoto T, et al. Detection of human bocavirus in the cerebrospinal fluid of children with encephalitis. Clin Infect Dis. 2012;54:964–7.
10. Manning A, Russell V, Eastick K, et al. Epidemiological profile and clinical associations of human bocavirus and other human parvoviruses. J Infect Dis. 2006;194:1283–90.
11. Schenk T, Strahm B, Konny U, et al. Disseminated bocavirus infection after stem cell transplant. Emerg Infect Dis. 2007;13:1425–7.
12. Schenk T, Maier B, Hufnagel M, et al. Persistence of human bocavirus DNA in immunocompromised children. Pediatr Infect Dis J. 2011;30:82–4.
13. Miyakis S, van Hal SJ, Barratt J, et al. Absence of human bocavirus in bronchoalveolar lavage fluid of lung transplant patients. J Clin Virol. 2009;44:179–80.
14. Soucal PM, Aubert J-D, Bridevaux P-O, et al. Upper and lower respiratory tract viral infection and acute graft rejection in lung transplant recipients. Clin Infect Dis. 2010;51:163–70.
15. Pialoux G, Gauzere B-A, Jaureguiberry S, Strobel M. Chikungunya, an epidemic arbovirus. Lancet Infect Dis. 2007;7:319–27.
16. Weaver SC, Lecuit M. Chikungunya virus and the global spread of a mosquito-borne disease. N Engl J Med. 2015;372:1231–9.
17. Leparc-Goffart I, Nougairede A, Cassadou S, et al. Chikungunya in the Americas. Lancet. 2014;383:514.
18. Couderc T, Gangeux N, Chretien F, et al. Chikungunya virus infection of corneal grafts. J Infect Dis. 2012;206:851–9.
19. Centers for Disease Control and Prevention (CDC). Revised U.S. surveillance case definition for severe acute respiratory syndrome (SARS) and update on SARS cases—United States and worldwide, December 2003. MMWR Morb Mortal Wkly Rep. 2003;52:1202–6.
20. Leung GM, Hedley AJ, Ho LM, et al. The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients. Ann Intern Med. 2004;141:662–73.
21. Vabret A, Dina J, Gouarin S, et al. Detection of the new human coronavirus HKU1: a report of 6 cases. Clin Infect Dis. 2006;42:634–9.
22. Tsang KW, Ho PL, Ooi GC, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348:1977–85.
23. Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348:1986–94.
24. Poutanen SM, Low DE, Henry B, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med. 2003;348:1995–2005.
25. Muller MP, Richardson SE, McGeer A, et al. Early diagnosis of SARS: lessons from the Toronto SARS outbreak. Eur J Clin Microbiol Infect Dis. 2006;25:230–7.
26. Roberts A, Thomas WD, Guamer J, et al. Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters. J Infect Dis. 2006;193:685–92.
27. Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348:1967–76.
28. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348:1953–66.
29. Booth TF, Kournikakis B, Bastien N, et al. Detection of airborne severe acute respiratory syndrome (SARS) coronavirus and environmental contamination in SARS outbreak units. J Infect Dis. 2005;191:1472–7.

30. Adachi D, Johnson G, Draker R, et al. Comprehensive detection and identification of human coronaviruses, including the SARS-associated coronavirus, with a single RT-PCR assay. J Virol Methods. 2004;122:29–36.

31. Kumar D, Tellier R, Draker R, et al. Severe acute respiratory syndrome (SARS) in a liver transplant recipient and guidelines for donor SARS screening. Am J Transplant. 2003;3:977–81.

32. Farcas GA, Poutanen SM, Mazzulli T, et al. Fatal severe acute respiratory syndrome is associated with multorgan involvement by coronavirus. J Infect Dis. 2005;191:193–7.

33. Xu J, Zheng S, Liu J, et al. Detection of severe acute respiratory syndrome coronavirus in the rain: potential role of the chemokine Mig in pathogenesis. Clin Infect Dis. 2005;41:1089–96.

34. Svoboda T, Henry B, Shulman L, et al. Public health measures to control the spread of the severe acute respiratory syndrome during the outbreak in Toronto. N Engl J Med. 2004;350:2352–61.

35. Gautret P, Gray GC, Charrel RN, et al. Emerging viral respiratory tract infections—environmental risk factors and transmission. Lancet Infect Dis. 2014;14:1113–22.

36. Drosten C, Seilmaier M, Corman VM, et al. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet. 2013;13:745–51.

37. Rasmussen SA, Gerber SI, Swerdlow DL. Middle East respiratory syndrome Coronavirus: update for clinicians. Clin Infect Dis. 2015;60(11):1686–9.

38. Arabi YM, Arifi AA, Balkhy HH, et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med. 2014;160:389–97.

39. Memish ZA, Zumla AI, Assiri A. Middle East respiratory syndrome coronavirus infections in health care workers. N Engl J Med. 2013;369:884–6.

40. Al-Abdallat MM, Payne DC, Alqasrawi S, et al. Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. Clin Infect Dis. 2014;59:1225–33.

41. Memish ZA, Cotton M, Meyer B, et al. Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia. 2013. Emerg Infect Dis. 2014;20(6):1012–5.

42. Alghamdi M, Mushtaq F, Awn N, Shaman N. MERS CoV infection in two renal transplant recipients: case report. Am J Transplant. 2015;15:1101–4.

43. Chan JFW, Chan K-H, Kao RYT, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect. 2013;67:606–16.

44. Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon–alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med. 2013;19:1313–7.

45. Omrani AS, Saad MM, Baig K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014;14:1090–5.

46. Garbino J, Crespo S, Aubert JD, et al. A prospective hospital based study of the clinical impact of non-severe acute respiratory syndrome (non-SARS)-related human coronavirus infection. Clin Infect Dis. 2006;43:1009–15.

47. Pene F, Merlat A, Vabret A. Coronavirus 229E-related pneumonia in immunocompromised patients. Clin Infect Dis. 2003;37:929–32.

48. Dalton HR, Bendall R, Ijaz S, Banks M. Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis. 2008;8:698–709.

49. Banks M, Heath GS, Grierson SS, et al. Evidence for the presence of hepatitis E virus in pigs in the United Kingdom. Vet Rec. 2004;154:223–7.

50. Wang YC, Zhang HY, Xia NS, et al. Prevalence, isolation and partial sequence analysis of hepatitis E virus from domestic animals in China. J Med Virol. 2002;67:516–21.

51. Mansuy JM, Legrand-Abravanel F, Calot JP, et al. High prevalence of anti-hepatitis E virus antibodies in blood donors from southwest France. J Med Virol. 2008;80:289–93.

52. Thomas DL, Yarbough PO, Vlahov D, et al. Seroreactivity to hepatitis E virus in areas where the disease is not endemic. J Clin Microbiol. 1997;35:1244–7.

53. Matsuda H, Okada K, Takahashi K, Mishiro S. Severe hepatitis E virus infection after ingestion of uncooked liver from a wild boar. J Infect Dis. 2003;188:944.

54. Matsuda H, Okada K, Takahashi K, Mishiro S. Zoonotic transmission of hepatitis E virus from deer to human beings. Lancet. 2003;362:371–3.

55. Feagins AR, Opriessnig T, Guenette DK, et al. Detection and characterization of infectious hepatitis E virus from commercial pig livers sold in local grocery stores in the USA. J Gen Virol. 2007;88:912–7.

56. Mitsu T, Tsukamoto Y, Yamazaki C, et al. Prevalence of hepatitis E virus infection among hemodialysis patients in Japan: evidence for infection with a genotype 3 HEV by blood transfusion. J Med Virol. 2004;74:563–72.

57. Boxall E, Herborn A, Kochethu G, et al. Transfusion-transmitted hepatitis E virus in a “nonhyperendemic” country. Transfus Med. 2006;16:79–83.

58. Khuroo MS, Kamili S, Yattoo GN. Hepatitis E infection may be transmitted through blood transfusions in an endemic area. J Gastroenterol Hepatol. 2004;19:777–84.

59. Matsubayashi K, Nagaoka Y, Sakata H, et al. Transfusion-transmitted hepatitis E caused by apparently indigenous hepatitis E virus strain in Hokkaido, Japan. Transfusion. 2004;44:394–40.

60. Clayson ET, Myint KS, Snitbhan R, et al. Viremia, fecal shedding and IgM and IgG responses in patients with hepatitis E. J Infect Dis. 1995;172:927–33.

61. Khuroo MS, Kamili S. Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy. J Viral Hepat. 2003;10:61–9.

62. Bhatia V, Singhal A, Panda SK, Acharya SK. A 20-year single center experience with acute liver failure during pregnancy: is the prognosis really worse? Hepatology. 2008;48:1577–85.

63. Halac U, Beland K, Lapierre P, et al. Chronic hepatitis E in children with liver transplantation. Gut. 2012;61:597–603.

64. Legrand-Abravanel F, Kamar N, Sands-Saune K, et al. Hepatitis E virus infection without reactivation in solid organ transplant recipients. France. Emerg Infect Dis. 2011;17:30–7.

65. Kamar N, Selves J, Mansuy J-M, et al. Hepatitis E virus and chronic hepatitis in solid organ transplant recipients. N Engl J Med. 2008;358:811–7.

66. leCoutre P, Meisel H, Hoffman J, et al. Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukemia after allogeneic stem cell transplantation. Gut. 2009;58:699–702.
67. Haagsma EB, Niesters HGM, van den Berg AP, et al. Prevalence of hepatitis E virus infection in liver transplant recipients. Liver Transpl. 2009;15:1225–8.
68. Versluis J, Pas SD, Agteresch HJ, et al. Hepatitis E virus: an underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation. Blood. 2013;122:1079–86.
69. Kamar N, Weclawiak H, Guilbeau-Frugier C, et al. Hepatitis E virus and the kidney in solid organ transplant patients. Transplantation. 2012;93:617–23.
70. Pischke S, Suneetha PV, Baechlein C, et al. Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl. 2010;16:74–82.
71. Kamar N, Izopet J, Cintas P, et al. Hepatitis E virus-induced neurological symptoms in a kidney-transplant patient with chronic hepatitis. Am J Transplant. 2010;10:1321–4.
72. Kamar N, Rostaing L, Abravanel F, et al. Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation. Clin Infect Dis. 2010;50:e30–3.
73. Kamar N, Rostaing L, Abravanel F, et al. Ribavirin therapy inhibits viral replication on patients with chronic hepatitis E virus infection. Gastroenterology, 2010;139:1612–8.
74. Fischer SA, Graham MB, Kuehnert MJ, et al. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med. 2006;354:2235–49.
75. Centers for Disease Control and Prevention (CDC). Lymphocytic choriomeningitis virus infection in organ transplant recipients – Massachusetts, Rhode Island, 2005. MMWR Morb Mortal Wkly Rep. 2005;54:537–9.
76. Paddock C, Ksiazek T, Comer JA, et al. Pathology of fatal lymphocytic choriomeningitis virus infection in multiple organ transplant recipients from a common donor. Mod Pathol. 2005;18 Suppl 1:S63A.
77. Palacios G, Druce J, Du L, et al. A new arenavirus in a cluster of fatal transplant-associated diseases. N Engl J Med. 2008;358:991–8.
78. Simmonds P. A new arenavirus in transplantation. N Engl J Med. 2008;358:2638–9.
79. Gregg MB. Recent outbreaks of lymphocytic choriomeningitis in the United States of America. Bull World Health Organ. 1975;52:549–53.
80. MacNeil A, Stoher U, Farnon E, et al. Solid organ transplant-associated lymphocytic choriomeningitis virus, United States, 2011. Emerg Infect Dis. 2012;18:1256–62.
81. Hirsch MS, Moelling Jr RC, Pope HG, et al. Lymphocytic choriomeningitis virus infection traced to a pet hamster. N Engl J Med. 1974;291:610–2.
82. Skinner HH, Knight EH. The potential role of Syrian hamsters and other small animals as reservoirs of lymphocytic choriomeningitis virus. J Small Anim Pract. 1979;20:145–61.
83. Childs JE, Glass GE, Ksiazek TG, et al. Human-rodent contact and infection with lymphocytic choriomeningitis and Seoul viruses in an inner city population. Am J Trop Med Hyg. 1991;44:117–21.
84. Amman BR, Pavlin BI, Albarino CG, et al. Pet rodents and fatal lymphocytic choriomeningitis in transplant patients. Emerg Infect Dis. 2007;13:719–25.
85. Warkel RL, Rinaldi CF, Bancroft WH, et al. Fatal acute meningocellulitis due to lymphocytic choriomeningitis virus. Neurology. 1973;23:198–203.
86. Dare R, Sanghavi S, Bullotta A, et al. Diagnosis of human metapneumovirus infection in immunocompromised lung transplant recipients and children evaluated for pertussis. J Clin Microbiol. 2007;45:548–52.
87. Esper F, Boucher D, Weibel C, et al. Human metapneumovirus infection in the United States: clinical manifestations associated with a newly emerging respiratory infection in children. Pediatrics. 2003;111:1407–10.
88. Bastien N, Ward D, Van Caeseele P, et al. Human metapneumovirus infection in the Canadian population. J Clin Microbiol. 2003;41:4642–6.
89. Esper F, Martinello RA, Boucher D, et al. A 1-year experience with human metapneumovirus in children aged <5 years. J Infect Dis. 2004;189:1388–96.
90. Boivin G, De Serres G, Hamelin ME, et al. An outbreak of severe respiratory tract infection due to human metapneumovirus in a long-term care facility. Clin Infect Dis. 2007;44:1152–8.
91. Sumino KC, Agapov E, Pierce RA, et al. Detection of severe human metapneumovirus infection by real-time polymerase chain reaction and histopathological assessment. J Infect Dis. 2005;192:1052–60.
92. Larcher C, Geltner C, Fischer H, et al. Human metapneumovirus infection in lung transplant recipients: clinical presentation and epidemiology. J Heart Lung Transplant. 2005;24:1891–901.
93. Dosanjh A. Respiratory metapneumovirus infection without co-infection in association with acute and chronic lung allograft dysfunction. J Inflamm Res. 2015;8:79–82.
94. Richards A, Chuen JN, Taylor C, et al. Acute respiratory infection in a renal transplant recipient. Nephrol Dial Transplant. 2005;20:2848–50.
95. Englund JA, Bociek M, Kuypers J, et al. Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med. 2006;144:344–9.
96. Debiaggi M, Canducci F, Sampaolo M, et al. Persistent symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients. J Infect Dis. 2006;194:474–8.
97. Gerna G, Vitulo P, Rovida F, et al. Impact of human metapneumovirus and human cytomegalovirus versus other respiratory viruses on the lower respiratory tract infections of lung transplant recipients. J Med Virol. 2006;78:408–16.
98. Hamlin ME, Prince GA, Boivin G. Effect of ribavirin and glucocorticoid treatment in a mouse model of human metapneumovirus infection. Antimicrob Agents Chemoth. 2006;50:774–7.
99. Raza K, Ismailjee SB, Crespo M, et al. Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. J Heart Lung Transplant. 2007;26:862–4.
100. Centers for Disease Control and Prevention (CDC). Import associated measles outbreak—Indiana, May–June 2005. MMWR Morb Mortal Wkly Rep. 2005;54:1073–75.
101. Centers for Disease Control and Prevention (CDC). Measles among adults associated with adoption of children in China—California, Missouri, and Washington, July–August 2006. MMWR Morb Mortal Wkly Rep. 2007;56:144–6.
102. Centers for Disease Control and Prevention (CDC). Multistate measles outbreak associated with an international youth sporting event—Pennsylvania, Michigan and Texas, August–September 2007. MMWR Morb Mortal Wkly Rep. 2008;57:169–73.
141. Ahmad K. Norwalk-like virus attacks troops in Afghanistan. Lancet Infect Dis. 2002;2:391.

142. Mattner F, Sohr D, Heim A, et al. Risk groups for clinical complications of norovirus infections: an outbreak investigation. Clin Microbiol Infect. 2006;12:69–74.

143. Said MA, Perl TM, Sears CL. Gastrointestinal flu: norovirus in health care and long-term care facilities. Clin Infect Dis. 2008;47:1202–8.

144. Cunha BA, Thekkel V, Eisenstein L. Community-acquired norovirus diarrheaa outbreak mimicking a community-acquired C. difficile diarrheaa outbreak. J Hosp Infect. 2008;70:98–100.

145. Centers for Disease Control and Prevention (CDC). Norovirus outbreak associated with a natural lake used for recreation – Oregon, 2014. MMWR Morb Mortal Wkly Rep. 2015;64:485–90.

146. Harris JP, Edmunds J, Pebody R, et al. Deaths from norovirus among the elderly, England and Wales. Emerg Infect Dis. 2008;14:1546–52.

147. Verhoef LPB, Kroneman A, van Duynhoven Y, et al. Selection tool for foodborne norovirus outbreaks. Emerg Infect Dis. 2009;15:31–8.

148. Patel MM, Widdowson M-A, Glass RI, et al. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg Infect Dis. 2008;14:1224–31.

149. Ludwig A, Adams O, Laws H-J, et al. Quantitative detection of norovirus excretion in pediatric patients with cancer and prolonged gastroenteritis and shedding of norovirus. J Med Virol. 2008;80:1461–7.

150. Roos-Weil D, Ambert-Balay K, Lanternier F, et al. Impact of norovirus/sapovirus-related diarrhea in renal transplant recipients hospitalized for diarrhea. Transplantation. 2011;92:61–9.

151. Robles JDR, Cheuk DKL, Ha SY, et al. Norovirus infection in pediatric hematopoietic stem cell transplantation recipients: incidence, risk factors, and outcome. Biol Blood Marrow Transplant. 2012;18:1883–9.

152. Schwartz S, Vergoulidou M, Schreier E, et al. Norovirus gastroenteritis causes severe and lethal complications after chemotherapy and hematopoietic stem cell transplantation. Blood. 2011;117:5850–6.

153. Schreier E, Doring F, Kunkel U. Molecular epidemiology of outbreaks of gastroenteritis associated with small round structured viruses in Germany in 1997/98. Arch Virol. 2000;145:443–53.

154. Kaufman SS, Cahitterjee NK, Fuschino ME, et al. Calicivirus enteritis in an intestinal transplant recipient. Am J Transplant. 2003;3:764–8.

155. Eid AJ, Posfay-Barbe KM and the AST Infectious Diseases Community of Practice. Am J Transplant. 2009;9 Suppl 4:S147–50.

156. Bonvicini F, Marinacci G, Pajno MC, et al. Meningoencephalitis with persistent parvovirus B19 infection in an apparently healthy woman. Clin Infect Dis. 2008;47:384–7.

157. Douvoyiannis M, Litman N, Goldman DL. Neurologic manifestations associated with parvovirus B19 infection. Clin Infect Dis. 2009;48:1713–23.

158. Klumpen H-J, Petersen EJ, Verdonck LF. Severe multiorgan failure after parvovirus B19 infection in an allogeneic stem cell transplant recipient. Bone Marrow Transplant. 2004;34:469–70.

159. Laurenz M, Winkelmann B, Roigas J, et al. Severe parvovirus B19 encephalitis after renal transplantation. Pediatr Transplant. 2006;10:978–81.

160. Park JB, Kim D-J, Woo S-Y, et al. Clinical implications of quantitative real-time polymerase chain reaction of parvovirus B19 in kidney transplant recipients – a prospective study. Transpl Int. 2009;22:455–62.

161. Yango A, Morrissey P, Goh R, et al. Donor-transmitted parvovirus infection in a kidney transplant recipient presenting as pancytopenia and allograft dysfunction. Transpl Infect Dis. 2002;4:163–6.

162. Wasak-Szulikowska E, Grabarczyk P, Rzepecki P. Pure red cell aplasia due to parvovirus B19 infection transmitted probably through hematopoietic stem cell transplantation. Transpl Infect Dis. 2008;10:201–5.

163. Muetherig A, Christopeit M, Muller LP, et al. Human parvovirus B19 infection with GvHD-like erythema in two allogeneic stem cell transplant recipients. Bone Marrow Transplant. 2007;39:315–6.

164. Plentz A, Hahn J, Holler E, et al. Long-term parvovirus B19 viraemia associated with pure red cell aplasia after allogeneic bone marrow transplantation. J Clin Virol. 2004;31:16–9.

165. Renoult E, Bachelet C, Krier-Coudert M-J, et al. Recurrent anemia in kidney transplant recipients with parvovirus B19 infection. Transplant Proc. 2006;38:2321–3.

166. Beckhoff A, Steffen I, Sandoz P, et al. Relapsing severe anemia due to primary parvovirus B19 infection after renal transplantation: a case report and review of the literature. Nephrol Dial Transplant. 2007;22:3660–3.

167. Ardalan MR, Shoja MM, Tubbs RS, Jayne D. Parvovirus B19 microepidemic in renal transplant recipients with thrombotic microangiopathy and allograft vasculitis. Exp Clin Transplant. 2008;6:143–7.

168. Ardalan MR, Shoja MM, Tubbs RS, et al. Postrenal transplant hemophagocytic lymphohistiocytosis and thrombotic microangiopathy associated with parvovirus B19 infection. Am J Transplant. 2008;8:1340–4.

169. Barzon L, Murer L, Pacenti M, et al. Investigation of intrarenal infections in kidney transplant recipients unveils an association between parvovirus B19 and chronic allograft injury. J Infect Dis. 2009;199:372–80.

170. Breinholt JP, Moulik M, Dreyer WJ, et al. Viral epidemiologic shift in inflammatory heart disease: the increasing involvement of parvovirus B19 in the myocardium of pediatric cardiac transplant patients. J Heart Lung Transplant. 2010;29:739–46.

171. Allander T, Andreasson K, Gupta S, et al. Identification of a third human polyomavirus. J Virol. 2007;81:4130–6.

172. Gaynor AM, Missen MD, Whiley DM, et al. Identification of a novel polyomavirus from patients with acute respiratory tract infections. PLoS Pathog. 2007;3:595–604.

173. Sharp CP, Norja P, Anthony I, Bell JE, Simmonds P. Reactivation and mutation of newly discovered WU, KI and Merkel Cell carcinoma polyomaviruses in immunosuppressed individuals. J Infect Dis. 2009;199:398–404.

174. Mourez T, Bergeron A, Ribaud P, et al. Polyomaviruses KI and WU in immunocompromised patients with respiratory disease. Emerg Infect Dis. 2009;15:107–9.

175. Dibiaggi M, Canducci F, Brerra R, et al. Molecular epidemiology of KI and WU polyomaviruses in infants with acute respiratory disease and in adult hematopoietic stem cell transplant recipients. J Med Virol. 2010;82:153–6.
176. Penn I, First MR. Merkel’s cell carcinoma in organ recipients: report of 41 cases. Transplantation. 1999;68:1717–21.
177. Stelzmueller I, Wiesmayer S, Swenson BR, et al. Rotavirus enteritis in solid organ transplant recipients: an underestimated problem? Transpl Infect Dis. 2007;9:281–5.
178. Yin Y, Metselaar HJ, Sprenger D, et al. Rotavirus in organ transplantation: drug-virus-host interactions. Am J Transplant. 2015;15:585–93.
179. Haber P, Patel M, Izuirieta HS, et al. Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006 to September 25, 2007. Pediatrics. 2008;121:1206–12.
180. Heyse JF, Kuter BJ, Dallas MJ, et al. Evaluating the safety of a rotavirus vaccine: the REST of the story. Clin Trials. 2008;5:131–9.
181. Reisinger KS, Block SL. Characteristics of an ideal rotavirus vaccine. Clin Pediatr. 2008;47:555–63.
182. Rubin LG, Levin MJ, Davies EG, et al. 2013 IDSA clinical guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:309–18.
183. Gubler DJ. The continuing spread of West Nile virus in the western hemisphere. Clin Infect Dis. 2007;45:1039–46.
184. Planitzer CB, Modrof J, Kreil TR. West Nile virus neutralization by US plasma-derived immunoglobulin products. J Infect Dis. 2007;196:435–40.
185. Nash D, Mostashari F, Fine A, et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med. 2001;344:1807–14.
186. Gea-Banacloche J, Johnson RT, Bagie A, et al. West Nile virus: pathogenesis and therapeutic options. Ann Intern Med. 2004;140:545–53.
187. Ferguson DD, Gershman K, LeBailly A, et al. Characteristics of the rash associated with West Nile virus fever. Clin Infect Dis. 2005;41:1204–7.
188. Sejvar JJ. The long-term outcomes of human West Nile virus infection. Clin Infect Dis. 2007;44:1617–24.
189. Bode AV, Sejvar JJ, Pape J, et al. West Nile virus disease: a descriptive study of 228 patents hospitalized in a 4-county region of Colorado in 2003. Clin Infect Dis. 2006;42:1234–40.
190. Sejvar JJ, Haddad MB, Tierney BC, et al. Neurologic manifestations and outcome of West Nile virus infection. JAMA. 2003;290:511–5.
191. Paddock CD, Nicholson WL, Bhatnager J, et al. Fatal hemorrhagic fever caused by West Nile virus in the United States. Clin Infect Dis. 2006;42:1527–35.
192. Centers for Disease Control and Prevention (CDC). Possible dialysis-related West Nile virus transmission-Georgia. 2003. MMWR Morb Mortal Wkly Rep. 2004;53:738–9.
193. Iwamoto M, Jernigan DB, Guasch A, et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med. 2003;348:2196–203.
194. Centers for Disease Control and Prevention (CDC). Public health dispatch: West Nile virus infection in organ donor and transplant recipients-Georgia and Florida, 2002. MMWR Morb Mortal Wkly Rep. 2002;51:790.
195. Centers for Disease Control and Prevention (CDC). Update: investigations of West Nile virus infections in recipients of organ transplantation and blood transfusion. MMWR Morb Mortal Wkly Rep. 2002;51:833–6.
196. Centers for Disease Control and Prevention (CDC). Public health dispatch: investigations of West Nile virus infections in recipients of blood transfusions. MMWR Morb Mortal Wkly Rep. 2002;51:973–4.
197. Barshes NR, Agee EE, Zgabay T, et al. West Nile virus encephalopathy following pancreatic islet transplantation. Am J Transplant. 2006;6:3037.
198. Shepard JC, Subramanian A, Montgomery RA, et al. West Nile virus encephalitis in a kidney transplant recipient. Am J Transplant. 2004;4:830–3.
199. Armali Z, Ramadan R, Chlebowski A, et al. West Nile virus encephalitis in organ transplant recipients: another high-risk group for meningoencephalitis and death. Transplantation. 2004;77:466–9.
200. Kumar D, Prasad GV, Zaltzman J, et al. Community-acquired West Nile virus infection in solid-organ transplant recipients. Transplantation. 2007;77:399–402.
201. Kleinenschmidt-DeMasters BK, Marder BA, Levi ME, et al. Naturally acquired West Nile virus encephalitis in transplant recipients: clinical, laboratory, diagnostic, and neuropathological features. Arch Neurol. 2004;61:1210–20.
202. Penn RG, Guerner J, Sejvar JJ, et al. Persistent neuroinvasive West Nile virus infection in an immunocompromised patient. Clin Infect Dis. 2006;42:680–3.
203. Hong DS, Jacobson KL, Raad II, et al. West Nile encephalitis in 2 hematopoietic stem cell transplant recipients: case series and literature review. Clin Infect Dis. 2003;37:1044–9.
204. Hiatt B, Desjardin L, Carter T, et al. A fatal case of West Nile virus infection in a bone marrow transplant recipient. Clin Infect Dis. 2003;37:129–31.
205. Tilley PA, Fox JD, Jayaraman GC, et al. Nucleic acid testing for West Nile virus RNA in plasma enhances rapid diagnosis of acute infection in symptomatic patients. J Infect Dis. 2006;193:1361–4.
206. Jordan I, Briese T, Fischer N, et al. Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells. J Infect Dis. 2000;182:1214–7.
207. Hamden A, Green P, Mendelson E, et al. Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis. Transpl Infect Dis. 2002;4:160–2.
208. Ben-Nathan D, Lustig S, Tam G, et al. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J Infect Dis. 2003;188:5–12.
209. Makhouf B, Braun E, Herskovitz M, et al. Hyperimmune gammaglobulin for the treatment of West Nile Virus encephalitis. Isr Med Assoc J. 2009;11:151–3.
210. Carson PJ, Konewko P, Wold KS, et al. Long-term clinical and neuropsychological outcomes of West Nile virus infection. Clin Infect Dis. 2006;43:723–30.
211. Morelli MC, Sambiri V, Grazi GL, et al. Absence of neuroinvasive disease in a liver transplant recipient who acquired West Nile Virus (WNV) infection from the organ donor and who received WNV antibodies prophylactically. Clin Infect Dis. 2010;51:e34–7.
213. Martin JE, Pierson TC, Hubka S, et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase I clinical trial. J Infect Dis. 2007;196:1732–40.
214. Funk GA, Gosert R, Hirsch HH. Viral dynamics in transplant patients: implications for disease. Lancet Infect Dis. 2007;7:460–72.
215. Wada K, Kubota N, Ito Y, et al. Simultaneous quantification of Epstein-Barr virus, cytomegalovirus, and human herpesvirus 6 DNA in samples from transplant recipients by multiplex real-time PCR assay. J Clin Microbiol. 2007;45:1426–32.
216. Smith TF, Espy MJ, Mandrekar J, et al. Quantitative real-time polymerase chain reaction for evaluating DNAemia due to cytomegalovirus, Epstein-Barr virus, and BK virus in solid-organ transplant recipients. Clin Infect Dis. 2007;45:1056–61.
217. Weinberg A, Zamora MR, Li S, et al. The value of polymerase chain reaction for the diagnosis of viral respiratory tract infections on lung transplant recipients. J Clin Virol. 2002;25:171–5.
218. Kumar D, Erdman D, Keshavjee S, et al. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant. 2005;5:2031–6.
219. Matar LD, McAdams HP, Palmer SM, et al. Respiratory viral infections in lung transplant recipients: radiologic findings with clinical correlation. Radiology. 1999;213:735–42.